7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
May 22, 2023 13:05 ET
|
7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies
June 09, 2022 19:53 ET
|
7 Hills Pharma
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual...
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET
|
7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma
March 08, 2022 17:32 ET
|
7 Hills Pharma
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small...
Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
January 27, 2022 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...
7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
November 01, 2021 15:08 ET
|
7 Hills Pharma
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
November 10, 2020 01:08 ET
|
Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 10:13 ET
|
ImmunoPhotonics, Inc.
ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 04:13 ET
|
ImmunoPhotonics, Inc.
BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers...
7 Hills Pharma Highlights Cell Adhesion as Key to Improving Effectiveness of Covid-19 Vaccines and Immuno-Oncology Drugs At BIO Digital 2020 Online Conference
June 15, 2020 10:39 ET
|
7 Hills Pharma
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical-stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...